Prostate Cancer
Clinical research is centered on metastatic castration-resistant prostate cancer, with interest in patients whose disease has progressed after androgen receptor axis-targeted therapy. The trial activity reflects a focus on advanced oncology care in the setting of treatment-resistant disease.
- Metastatic castration-resistant prostate cancer
- Androgen receptor axis-targeted therapy resistance
- Advanced prostate cancer
The research landscape is concentrated on treatment options for men with progressive disease after hormonal therapy, with attention to radiographic progression in advanced prostate cancer.
Radioligand Therapy
Investigational work includes lutetium-based radioligand therapy for prostate cancer, with emphasis on targeting disease through radiopharmaceutical approaches. This area aligns with interest in precision-directed treatment for advanced solid tumours.
- Lutetium-177-based treatment
- Radiopharmaceutical therapy
- Targeted radionuclide therapy
Research activity is directed toward therapies designed to interfere with disease progression in patients with advanced prostate cancer.
Hormone-Refractory Disease
Clinical interest extends to hormone-refractory prostate cancer, particularly after progression on standard androgen receptor inhibitors such as abiraterone and enzalutamide. This positions the sponsor within the treatment landscape for later-line urologic oncology.
- Hormone-refractory prostate cancer
- Abiraterone
- Enzalutamide
The therapeutic focus is on patients who have exhausted common hormonal options and require alternative approaches for disease control.
Advanced Oncology Networks
The sponsor’s trial activity spans multiple countries and collaborating sites, supporting research in multinational oncology settings. This includes coordinated clinical work in advanced cancer populations across different treatment centers.
- Multicenter oncology
- Cross-border clinical research
- Advanced solid tumour care
Current activity is focused on recruiting patients with advanced disease, reflecting sustained interest in specialized prostate cancer research within international clinical networks.
